MAIA ▼ -1.5% - MAIA Biotechnology, Inc. $MAIA - MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal MAIA Biotechnology shares fell 1.5% today despite the company's announcement that it is expanding its pivotal Phase 3 THIO-104 trial for non-small cell lung cancer into Spain and Portugal. The geographic expansion of the trial suggests progress in enrollment efforts, though the market's modest decline suggests investors may be pricing in the operational costs associated with broadening the study's footprint. 23-SEP-2026 09:17 AM ET